BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Key PointsBioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines.
BioNTech and Moderna, two companies that came to prominence during the COVID-19 pandemic, have seen their financial performance decline as the crisis subsided. These mRNA-based vaccine developers have struggled to keep up with the broader market over the past five years. However, there may be a promising future ahead for both companies as they move forward with their vaccine candidates.
BioNTech, known for its deep pipeline of candidates, has a particularly exciting molecule in the works called pumitamig. This drug is being developed in collaboration with Bristol Myers Squibb (NYSE: BMY). What sets pumitamig apart is its potential to challenge Merck's (NYSE: MRK) blockbuster cancer medication, Keytruda. Merck's Keytruda has been the world's best-selling cancer drug, so a competitor like pumitamig could significantly impact Merck's market position.
BioNTech is currently testing pumitamig in several potential cancer indications, with lung cancer being the top priority. Given that lung cancer is the leading cause of cancer-related deaths, success in this area could be particularly significant. Positive results from pumitamig clinical trials could lead to a substantial boost in BioNTech's stock price.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
